The best GLP-1 providers — one winner per honest category
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
"Best" is honest only per category, so this page names one winner per question and shows the computation. Lowest month-to-month tirzepatide: NexLife↗ at $215 all-in. Lowest 12-month all-in tirzepatide: NexLife at $2,232 on its prepaid year. Lowest broadly available semaglutide: Yucca Health↗ at $146 (overall floor: Oak Longevity, $133, limited states). Lowest introductory price: Fifty 410↗ at $133 — starter-only, unrankable at maintenance, listed so you know exactly what that number is. Best for insurance: Ro, whose $145/mo membership funds coverage navigation for brand medication. Best flat-rate structure: NexLife. Best no-commitment path: NexLife — month-to-month, cancel anytime, no membership. Best brand access: LillyDirect↗ for Zepbound vials ($299–$449), NovoCare↗ for Wegovy ($349).
Every winner above is the output of a sort on the public dataset, not a placement; change the data and the winners change. Programs below are the category leaders in rank order of their headline figures, with structure notes.
RANK01
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$215/MO ALL-IN
RANK02
Yucca Health
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$258/MO ALL-IN
RANK04
LillyDirect (Zepbound)
No membership fee; shipping included; names its pharmacy network.
SOURCE-VERIFIED · captured 2026-08-09 · source
$449/MO ALL-IN
RANK05
NovoCare Pharmacy (Wegovy)
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
SOURCE-VERIFIED · captured 2026-08-10 · source
$349/MO ALL-IN
RANK06
Mochi Health
Dose-flat — the maintenance price equals the starter price; $79/mo membership already inside the figure; shipping included.
$278/MO ALL-IN
Best-for categories we refuse to award: "best results" and "best clinical quality" — outcomes depend on medication, dose, and person, none of which a pricing database can grade. Where clinical evidence matters (SURMOUNT-5's tirzepatide-vs-semaglutide result, oral absorption), we cite it in the analysis section rather than converting it into a badge.
The leaders, across a full year
Monthly figures flatter everyone equally; a year separates them. The field, annualized on the same all-in basis: NexLife: $2,580 monthly-billed, $2,232 on its prepaid path (upfront); Yucca Health: $3,096 monthly-billed; LillyDirect (Zepbound): $5,388 monthly-billed; Mochi Health↗: $3,336 monthly-billed.
Spread top-to-bottom within just these five: $756 a year — before considering the rest of the field, where the verified ceiling reaches $3,336. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 4 priced programs above: 3 are dose-flat, 3 carry no membership, 3 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
How to use a list like this well: shortlist two or three, pull each provider page, and read the record — structure, exit terms, pharmacy transparency, evidence flags — before letting the price column decide. The ranking gets you to the right neighborhood; the records keep you out of the wrong house.
Frequently asked
What is the cheapest option on this list?
NexLife at $215 per month all-in on the maintenance basis, captured 2026-08-10. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.